06-27-2009, 12:05 PM
<!--emo&:thumbsup--><img src='style_emoticons/<#EMO_DIR#>/thumbup.gif' border='0' style='vertical-align:middle' alt='thumbup.gif' /><!--endemo--> "CHIP may be a useful therapeutic target for treatments to break down LRRK2 in people with Parkinson's," said Goldberg.
He added: "Our next step is to identify cellular mechanisms that signal LRRK2 to be degraded by CHIP or by other mechanisms. Because LRRK2 mutations are believed to cause Parkinsonism by increasing the activity of LRRK2, enhancing the normal mechanisms that target LRRK2 for degradation by CHIP may be therapeutically beneficial."
The study has been published in the journal Public Library of Science.
http://timesofindia.indiatimes.com/Health-...how/4709750.cms
He added: "Our next step is to identify cellular mechanisms that signal LRRK2 to be degraded by CHIP or by other mechanisms. Because LRRK2 mutations are believed to cause Parkinsonism by increasing the activity of LRRK2, enhancing the normal mechanisms that target LRRK2 for degradation by CHIP may be therapeutically beneficial."
The study has been published in the journal Public Library of Science.
http://timesofindia.indiatimes.com/Health-...how/4709750.cms